Centocor, Inc. and Schering-Plough received approval from the European Commission for a new indication for Remicade for the treatment of severe, active Crohn’s disease (CD) in pediatric patients, aged 6 to 17 years, who have not responded to conventional therapy. Remicade has been studied only in combination with conventional immunosuppressive therapy. Remicade is the first biologic therapy approved in the EU for the treatment of pediatric CD, a condition that causes inflammation of...